Trials / Completed
CompletedNCT00631917
A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension
A 54 Week, Randomized, Double-blind, Parallel-group, Multicenter Study Evaluating the Long-term Gastrointestinal (GI) Safety and Tolerability of Aliskiren (300 mg) Compared to Ramipril (10 mg) in Patients With Essential Hypertension
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 774 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the long-term gastrointestinal (GI) safety and efficacy of aliskiren (300 mg) compared to ramipril (10mg) in patients ≥ 50 years with essential hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aliskiren | Aliskiren 300 mg once a day |
| DRUG | Ramipril | Ramipril 10 mg once a day |
| OTHER | Placebo to Ramipril | Placebo capsules to match ramipril. |
| OTHER | Placebo to Aliskiren | Placebo tablets to match aliskiren. |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2008-03-10
- Last updated
- 2011-07-12
- Results posted
- 2011-06-21
Locations
7 sites across 7 countries: United States, Argentina, Colombia, France, Germany, India, Spain
Source: ClinicalTrials.gov record NCT00631917. Inclusion in this directory is not an endorsement.